4201. Partnering For Progress: Implementing AI to Transform the Care Journey For Patients With Cardiac Amyloidosis

Sponsored by AstraZeneca

This session focuses on collaborative development of innovative AI-based programs for identifying and tracking patients with amyloidosis and generating structured clinical workflows for treatment and management. The presentation will delve into key considerations for implementation, partnership, and scalability, with the goal of inspiring cardiology colleagues by showcasing practical examples and encouraging them in their own initiatives.

Speakers

Leticia A. Funari Ferri, MD, MSc, PhD, MBA
US Medical Head, ATTR
AstraZeneca

Faraz S. Ahmad, MD, MS
Associate Director
Bluhm Cardiovascular Institute Center for AI
Northwestern Medicine
Assistant Professor, Medicine (Cardiology) and Preventive Medicine (Biostatistics and Informatics)
Northwestern University Feinberg School of Medicine
Chicago, IL

4202. Transforming Heart Failure Management: Using ZOLL Heart Failure Management System (HFMS) to Reduce Heart Failure Readmissions

Sponsored by ZOLL

This program will focus on best practices for building a clinical workflow and implementing ZOLL HFMS into the established treatment pathway for patients with pulmonary fluid congestion. The speaker will share experience from his center's experience with patient selection, managing alerts and implementing care changes to reduce HF readmissions.

Speaker

Timothy Malinowski, Jr., MS, APRN, AGPCNP-BC

4203. Long-Term Outcomes and Real-World Impact of Cardiac Myosin Inhibition on Adults With Symptomatic NYHA Class II-III Obstructive HCM

Sponsored by Bristol Myers Squibb

Join this session to review data from long-term and real-world studies on the impact of cardiac myosin inhibition in adult patients with symptomatic NYHA Class II-III obstructive HCM.

Speaker

Matthew Gold, MD

4204. Title to be announced

Sponsored by GE Healthcare

4205. Access to Cardiovascular Care Powered by Breakthrough Artificial Intelligence: India

Sponsored by Siemens Healthineers

4207. Evolut 5-Year Low Risk In-Depth Analysis and Lifetime Management Considerations

Sponsored by Medtronic

Join us as we dive into the latest TAVR verses SAVR 5-year low-risk results and hear lifetime management and index valve discussions from structural heart experts.

Speakers

Anita Asgar, MD
Michael Reardon, MD
Deepak Talreja, MD

4208. Equity in Action: The Evolut Evidence and Advantage For Women With Aortic Stenosis

Sponsored by Medtronic

Join us for an exciting multidisciplinary team discussion on identifying sex-specific differences in diagnosing aortic stenosis and treatment considerations with supporting evidence from the SMART trial.

Speakers

Elana Koss, MD
Rachel Bond, MD
Amit Vora, MD

4209. Decoding a Silent Threat: How Aldosterone Raises Your Risk For Hypertension and Heart Disease

Sponsored by AstraZeneca

Explore the pivotal role of aldosterone dysregulation within the hypertension landscape and its implications on cardiovascular health, even independent of blood pressure. Despite medical interventions, many continue to experience uncontrolled hypertension, leading to increased mortality, cardiovascular, and kidney complications. This presentation reveals cutting-edge insights into the pathogenic effects of aldosterone excess, such as cardiac remodeling and vascular inflammation, contributing to heart failure, cardiovascular disease, and chronic kidney disease. Be part of the conversation to ignite a transformative dialogue on redefining hypertension management.

Speakers

Florian Rader, MD
Medical Director, Hypertension Center
Cedars Sinai Smidt Heart Institute

4210. AI-Driven Plaque Quantification: A Paradigm Shift in CAD Management

Sponsored by HeartFlow

This session explores how AI-driven plaque quantification is transforming coronary artery disease (CAD) management. Experts will discuss how advanced imaging and AI tools are reshaping diagnosis, risk stratification, and treatment decisions, offering a paradigm shift in personalized care.

Speaker

Allen J. Taylor, MD, FACC, FAHA
Chairman of Cardiology
MedStar Heart and Vascular Institute

4211. Getting to the Heart of the Matter: Gene Therapy For Cardiac Disease

Sponsored by Lexeo Therapeutics

Cardiac diseases due to a genetic cause are common, but underrecognized culprits of potentially devastating outcomes. Opportunities exist to improve upon current treatments by targeting the underlying cause. Advancements in genetic medicine and delivery technologies have paved a path for cardiac gene therapy to get to the heart of the matter.

Join Drs. Eric Smith and Eric Adler to for an exciting discussion on the potential of gene therapy in arrhythmogenic cardiomyopathy (ACM) and hypertrophic cardiomyopathy.

Also hear about Lexeo's clinical progress, including new data updates, from their HEROIC-PKP2 gene therapy trial for PKP2-ACM and SUNRISE-FA gene therapy trial for Friedreich ataxia cardiomyopathy.

Speakers

Eric Smith, MD
Eric Adler, MD